Alex Schmitz
Partner @ Endeavour Vision
Geneva, Switzerland
Alex Schmitz is a Series E investor at Endeavour Vision in Geneva focused on Health Care and Biotechnology. Alexander Schmitz is an Investment Director at Endeavour Vision, a Geneva-based venture capital firm investing in growth-stage medical device and digital health companies.Alex has nearly two decades of business and strategy experience in both medical device and high-technology companies. From 2005 to 2014, he helped Biosensors InternationalGroup develop its interventional cardiology business, from less than $5 million in annual revenues to more than $300 million. He played a key role in establishing and building the company’s presence across Europe and Asia, most recently serving as vice president of business development, based in Switzerland.Prior to Biosensors, Alex spent three years with LogiSpring, the corporate venture fund of the TNT Post Group. He previously worked for MicroStrategy, a leading provider of business intelligence software. Alex began his career as a consultant at McKinsey & Company, where he served clients in the aerospace and telecommunications industries, and spent a year with the McKinsey Global Institute.He earned an MBA from INSEAD and a BSFS, magna cum laude, from Georgetown University’s School of Foreign Service, where he was a Krogh Scholar and a member of Phi Beta Kappa.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 42%
Last updated:
For AI agents: llms.txt
Industries Alex Schmitz invests in
Stages Alex Schmitz invests in
Countries Alex Schmitz invests in
Investment Focus
Industry
- Health Care 6 (50%)
- Biotechnology 4 (33%)
- Medical 3 (25%)
- Hospital 2 (17%)
- Medical Device 2 (17%)
Stage
- Series E 2 (17%)
- Funding Round 2 (17%)
- Series A 1 (8%)
- Series B 1 (8%)
- Series C 1 (8%)
Country
- United States 5 (42%)
- Germany 1 (8%)
- United Kingdom 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Gynesonics
|
Gynesonics is a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions. Gynesonics serves customers worldwide. It was founded in 2005 and is headquartered in Redwood City, California. | $42.5M / Oct 25, 2023 | |
Venture Med Group
|
VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients.Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly costeffective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device. | Convertible Note / Jan 31, 2023 | |
Kenbi
|
Kenbi is a nurse centric outpatient care company. | $26.6M / Series A / Dec 16, 2021 | |
|
Venture Med Group
|
VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients.Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly costeffective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device. | Convertible Note / Nov 23, 2021 | |
Relievant Medsystems
|
Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain. | $70M / Oct 29, 2020 | |
|
Relievant Medsystems
|
Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain. | $70M / Series F / Oct 29, 2020 | |
Lumeon
|
Lumeon is a digital health company that has defined the market for Care Pathway Management (CPM). From scheduling and revenue management to clinical reporting and aftercare, by looking across the end-to end care pathway, Lumeon addresses the system, and not just the symptom, behind healthcare transformation. Lumeon's customers number amongEurope’s fastest growing and most innovative healthcare providers including BUPA, Nuffield Health, Alliance Medical, HCA, Optegra and Newmedica. It is headquartered in London employing over 90 people. | $30M / Series D / Aug 11, 2020 | |
Rapid Micro Biosystems
|
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts. | $120M / Private Equity / May 20, 2020 | |
Nuvaira
|
Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease.It was founded in 2008and headquartered in Minneapolis, Minnesota. | $79M / Series E / Feb 11, 2019 | |
|
Relievant Medsystems
|
Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain. | $58M / Series E / Jun 26, 2018 | |
| See all 12 investments → | |||
Co-Investors
About Endeavour Vision
Endeavour Vision is a private equity firm investing in growth-stage MedTech and digital health companies. The company invests in medical innovation that provides superior clinical benefits for patients or brings significant efficiencies to health systems. Endeavour Vision team offers strategic and operational expertise and extensive internationalexperience investing in companies in Europe and North America. We have a proven track record of successful exits with recently realized investments that include Vertiflex (acquired by Boston Scientific in 2019), Medartis (IPO on SIX in Q1 2018), and Symetis (acquired by Boston Scientific in 2017). Endeavour Vision’s offices are located in Geneva, Switzerland, and Minneapolis, U.S.
Endeavour Vision Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alex Schmitz
Partner
|
|||
Bernard Vogel
Founder and Managing Partner
|
|||
Damien Tappy
President & Managing Partner
|
|||
Daniel van den Bergh
Senior Investment Director
|
|||
Fernando Pacheco
Investment Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Alex Schmitz invest in?
Alex Schmitz invests primarily in Health Care, Biotechnology and Medical startups, most often at Series E and Funding Round stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alex Schmitz last invest?
The most recent investment recorded for Alex Schmitz closed in Oct 2023. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
